239 related articles for article (PubMed ID: 20031551)
1. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Voora D; Shah SH; Reed CR; Zhai J; Crosslin DR; Messer C; Salisbury BA; Ginsburg GS
Circ Cardiovasc Genet; 2008 Dec; 1(2):100-6. PubMed ID: 20031551
[TBL] [Abstract][Full Text] [Related]
2. Comparison of statins in hypertriglyceridemia.
Stein EA; Lane M; Laskarzewski P
Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817
[TBL] [Abstract][Full Text] [Related]
3. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
4. Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Ruaño G; Thompson PD; Kane JP; Pullinger CR; Windemuth A; Seip RL; Kocherla M; Holford TR; Wu AH
Pharmacogenomics; 2010 Jul; 11(7):959-71. PubMed ID: 20602615
[TBL] [Abstract][Full Text] [Related]
5. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
9. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
10. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
[TBL] [Abstract][Full Text] [Related]
11. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
Donnelly LA; Palmer CN; Whitley AL; Lang CC; Doney AS; Morris AD; Donnan PT
Pharmacogenet Genomics; 2008 Apr; 18(4):279-87. PubMed ID: 18334912
[TBL] [Abstract][Full Text] [Related]
13. Characterization of statin dose response in electronic medical records.
Wei WQ; Feng Q; Jiang L; Waitara MS; Iwuchukwu OF; Roden DM; Jiang M; Xu H; Krauss RM; Rotter JI; Nickerson DA; Davis RL; Berg RL; Peissig PL; McCarty CA; Wilke RA; Denny JC
Clin Pharmacol Ther; 2014 Mar; 95(3):331-8. PubMed ID: 24096969
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
15. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.
Kajinami K; Brousseau ME; Nartsupha C; Ordovas JM; Schaefer EJ
J Lipid Res; 2004 Apr; 45(4):653-6. PubMed ID: 14703505
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
18. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
Wierzbicki AS; Mikhailidis DP
Int J Cardiol; 2002 Jul; 84(1):53-7. PubMed ID: 12104065
[TBL] [Abstract][Full Text] [Related]
19. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
